NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis $7.35 +0.30 (+4.26%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$7.34 -0.01 (-0.14%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About SOPHiA GENETICS Stock (NASDAQ:SOPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SOPHiA GENETICS alerts:Sign Up Key Stats Today's Range$6.90▼$7.4150-Day Range$6.49▼$8.9252-Week Range$3.83▼$8.98Volume455,314 shsAverage Volume628,647 shsMarket Capitalization$616.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data. The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting. Its applications are designed for areas such as oncology, hereditary disease and rare disease, helping clinicians and laboratories use genomic information to support diagnosis, treatment selection and research. Founded in Switzerland, SOPHiA GENETICS serves hospitals, clinical laboratories, biopharmaceutical companies and research institutions internationally. The company was co-founded by Jurgi Camblong, who has served as its chief executive officer, and has built a global network focused on expanding the use of data-driven precision medicine.AI Generated. May Contain Errors. Read More SOPHiA GENETICS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreSOPH MarketRank™: 3.17702070808 of 5 starsSOPHiA GENETICS scored higher than 64% of companies evaluated by MarketBeat, and ranked 411th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingSOPHiA GENETICS has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSOPHiA GENETICS has a consensus price target of $10.00, representing about 36.1% upside from its current price of $7.35.Amount of Analyst CoverageSOPHiA GENETICS has only been the subject of 3 research reports in the past 90 days.Read more about SOPHiA GENETICS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.77) to ($0.31) per share.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 10.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SOPHiA GENETICS's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.40% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 1.71, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 4.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.90 News SentimentSOPHiA GENETICS has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for SOPHiA GENETICS this week, compared to 5 articles on an average week.MarketBeat Follows3 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,970,799.00 in company stock.Percentage Held by Insiders4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by Institutions31.59% of the stock of SOPHiA GENETICS is held by institutions.Read more about SOPHiA GENETICS's insider trading history. Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SOPH Stock News HeadlinesSOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026October 20, 2026 | prnewswire.comSOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Zhenyu Xu Sells 4,000 SharesOctober 15, 2026 | insidertrades.comMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in value. Now gold has pulled back roughly 20%. Inflation is rising, the Fed is hiking rates, and government borrowing continues. Ross Givens says his long-term thesis still holds. He points to a backdoor gold play that ran 846%, 1,668%, and 1,915% in the last major cycle.October 24 at 1:00 AM | Traders Agency (Ad)Sophia Genetics, Myriad Genetics Collaborate on Prostate Cancer BiomarkerOctober 10, 2026 | finance.yahoo.comSOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score TechnologyOctober 8, 2026 | rttnews.comMyriad, SOPHiA partner with AstraZeneca to use prostate cancer technologyOctober 8, 2026 | msn.comSOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider George Cardoza Sells 1,592 SharesOctober 8, 2026 | insidertrades.comSOPHiA GENETICS SA (SOPH)September 18, 2026 | finance.yahoo.comSee More Headlines SOPH Stock Analysis - Frequently Asked Questions How have SOPH shares performed this year? SOPHiA GENETICS's stock was trading at $4.67 at the beginning of the year. Since then, SOPH stock has increased by 57.4% and is now trading at $7.35. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) issued its earnings results on Wednesday, August, 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05. The business earned $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative trailing twelve-month return on equity of 132.47%. Read the conference call transcript. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an IPO on Wednesday, July 21st 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. Who are SOPHiA GENETICS's major shareholders? SOPHiA GENETICS's top institutional investors include Sowell Financial Services LLC (0.41%) and Sowell Financial Services LLC (0.41%). Insiders that own company stock include Jurgi Camblong, Ross Muken, Zhenyu Xu, Well Daan Van, George Cardoza, Manuela Valente, Philippe Menu, Abhimanyu Verma, Kevin Puylaert and Kathy L Hibbs. View institutional ownership trends. How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SOPHiA GENETICS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Caribou Biosciences (CRBU), Micron Technology (MU), Advanced Micro Devices (AMD), Marvell Technology (MRVL) and Tesla (TSLA). Company Calendar Last Earnings8/05/2026Today10/24/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SOPH's financial health is in the Green zone, according to TradeSmith. SOPH has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolNASDAQ:SOPH CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees415Year Founded2011Price Target and Rating Average Price Target for SOPHiA GENETICS$10.00 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+36.1%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79 million Net Margins-93.86% Pretax Margin-93.19% Return on Equity-132.47% Return on Assets-45.97% Debt Debt-to-Equity Ratio0.58 Current Ratio2.69 Quick Ratio2.55 Sales & Book Value Annual Sales$77.27 million Price / Sales7.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book10.65Miscellaneous Outstanding Shares83,890,000Free Float79,801,000Market Cap$616.59 million OptionableOptionable Beta0.95 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SOPH) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in val...Traders Agency | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
